# A Study on the Bioequivalence of Bupivacaine Liposome Injection in Humans

> **NCT07279155** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Postoperative Local Analgesia

## Interventions

- **DRUG:** Bupivacaine Liposome Injection T preparation
- **DRUG:** Bupivacaine Liposome Injection R preparation

## Key facts

- **NCT ID:** NCT07279155
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-09
- **Primary completion:** 2025-07-21
- **Final completion:** 2025-07-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07279155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07279155, "A Study on the Bioequivalence of Bupivacaine Liposome Injection in Humans". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07279155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*